<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00219</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> Why is the transfer of recombinant DNA necessary for the proposed research?  <!-- PJG 0012 frnewline --> What questions can be answered by using recombinant DNA?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;A&hyph;2&hyph;b. What alternative methodologies exist? What are their  <!-- PJG 0012 frnewline --> relative advantages and disadvantages as compared to the use of recombinant  <!-- PJG 0012 frnewline --> DNA?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Appendix M&hyph;I&hyph;B. Research Design, Anticipated Risks and Benefits  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;I&hyph;B&hyph;1. Structure and Characteristics of the Biological System.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Provide a full description of the methods and reagents to be employed for gene  <!-- PJG 0012 frnewline --> delivery and the rationale for their use. The following are specific points to be  <!-- PJG 0012 frnewline --> addressed:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;1&hyph;a. What is the structure of the cloned DNA that will be used?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;1&hyph;a&hyph;(1). Describe the gene (genomic or cDNA), the bacterial  <!-- PJG 0012 frnewline --> plasmid or phage vector, and the delivery vector (if any). Provide complete  <!-- PJG 0012 frnewline --> nucleotide sequence analysis or a detailed restriction enzyme map of the total  <!-- PJG 0012 frnewline --> construct.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;1&hyph;a&hyph;(2). What regulatory elements does the construct contain  <!-- PJG 0012 frnewline --> (e.g., promoters, enhancers, polyadenylation sites, replication origins, etc.)? From  <!-- PJG 0012 frnewline --> what source are these elements derived? Summarize what is currently known  <!-- PJG 0012 frnewline --> about the regulatory character of each element.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;1&hyph;a&hyph;(3). Describe the steps used to derive the DNA construct.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;1&hyph;b. What is the structure of the material that will be  <!-- PJG 0012 frnewline --> administered to the patient?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;1&hyph;b&hyph;(1). Describe the preparation, structure, and composition of  <!-- PJG 0012 frnewline --> the materials that will be given to the patient or used to treat the patient's cells:  <!-- PJG 0012 frnewline --> (i) If DNA, what is the purity (both in terms of being a single DNA species and in  <!-- PJG 0012 frnewline --> terms of other contaminants)? What tests have been used and what is the  <!-- PJG 0012 frnewline --> sensitivity of the tests? (ii) If a virus, how is it prepared from the DNA construct?  <!-- PJG 0012 frnewline --> In what cell is the virus grown (any special features)? What medium and serum  <!-- PJG 0012 frnewline --> are used? How is the virus purified? What is its structure and purity? What steps  <!-- PJG 0012 frnewline --> are being taken (and assays used with their sensitivity) to detect and eliminate any  <!-- PJG 0012 frnewline --> contaminating materials (for example, VL30 RNA, other nucleic acids, or proteins)  <!-- PJG 0012 frnewline --> or contaminating viruses (both replication-competent or replication-defective) or  <!-- PJG 0012 frnewline --> other organisms in the cells or serum used for preparation of the virus stock  <!-- PJG 0012 frnewline --> including any contaminants that may have biological effects? (iii) If co-cultivation  <!-- PJG 0012 frnewline --> is employed, what kinds of cells are being used for co-cultivation? What steps are  <!-- PJG 0012 frnewline --> being taken (and assays used with their sensitivity) to detect and eliminate any  <!-- PJG 0012 frnewline --> contaminating materials? Specifically, what tests are being conducted to assess the  <!-- PJG 0012 frnewline --> material to be returned to the patient for the presence of live or killed donor cells  <!-- PJG 0012 frnewline --> or other non-vector materials (for example, VL30 sequences) originating from  <!-- PJG 0012 frnewline --> those cells? (iv) If methods other than those covered by Appendices M&hyph;I&hyph;B&hyph;1&hyph;b-(1)-(i) through (iii) are used to introduce new genetic information into target cells,  <!-- PJG 0012 frnewline --> what steps are being taken to detect and eliminate any contaminating materials?  <!-- PJG 0012 frnewline --> What are possible sources of contamination? What is the sensitivity of tests used  <!-- PJG 0012 frnewline --> to monitor contamination?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;1&hyph;b-(2). Describe any other material to be used in preparation of  <!-- PJG 0012 frnewline --> the material to be administered to the patient. For example, if a viral vector is  <!-- PJG 0012 frnewline --> proposed, what is the nature of the helper virus or cell line? If carrier particles  <!-- PJG 0012 frnewline --> are to be used, what is the nature of these?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;I&hyph;B&hyph;2. Preclinical Studies, Including Risk-Assessment Studies.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Provide results that demonstrate the safety, efficacy, and feasibility of the proposed  <!-- PJG 0012 frnewline --> procedures using animal and/or cell culture model systems, and explain why the  <!-- PJG 0012 frnewline --> model(s) chosen is/are most appropriate.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            